Key facts
- This page summarizes Garry A. Nicholson's Form 4 filing for Turning Point Therapeutics, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Aug 2022, 16:43.
Garry A. Nicholson - 17 Aug 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Aug 2022, 16:43:52 UTC
- Prior SEC filing
- 24 Jun 2022
- Next SEC filing
- 14 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paolo Tombesi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garry A. Nicholson filed Form 4 for Turning Point Therapeutics, Inc. on 17 Aug 2022.
Change
- Previous filing in this sequence was filed on 24 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TPTX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -23,400
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,400
- Exercise price
- $59.11
- Footnotes
- F1, F2
TPTX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -8,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,500
- Exercise price
- $65.64
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Garry A. Nicholson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
Footnote F2
At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.